Negative in Ames, in vitro micronucleus (human lymphocytes) and in vivo rat micronucleus assays
“Tazemetostat did not cause genetic damage in a standard battery of studies including a screening and pivotal bacterial reverse mutation (Ames) assay, an in vitro micronucleus assessment in human peripheral blood lymphocytes, and an in vivo micronucleus assessment in rats after oral administration.”
Not conducted (advanced cancer indication); rodent studies show clear carcinogenic potential
“Dedicated carcinogenicity studies were not conducted with tazemetostat and are not required to support the use of a drug intended to treat patients with advanced cancer; however, findings in the rodent studies demonstrate that the drug has clear carcinogenic potential”
✓ VerifiedFDA multi-discipline review, p. 34Source ↗
Reproductive & developmental
Rat and rabbit EFD: dose-dependent skeletal developmental abnormalities from ~1.5x human exposure
“Administration of tazemetostat to pregnant rats and rabbits during organogenesis resulted in dose-dependent increases in skeletal developmental abnormalities in both species beginning at maternal exposures approximately 1.5 times the adult human exposure”
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative